Interestingly, this very rapid tumour reduction occurred in the presence of NOTCH1 mutation; whether obinutuzumab can overcome the negative impact of this mutation in CLL awaits further studies. Here, NOTCH1 is linked to B-cell chronic lymphocytic leukemia.